Rett syndrome is a genetically based neurodevelopmental disorder. Although the clinical consequences of Rett syndrome are profound and lifelong, currently no approved drug treatments are available specifically targeted to Rett symptoms. High quality outcome measures, specific to the core symptoms of a disorder are a critical component of well-designed clinical trials for individuals with neurodevelopmental disorders. The Clinical Global Impression Scale is a measure of global clinical change with strong face validity that has been widely used as an outcome measure in clinical trials of central nervous system disorders. Despite its favorable assay sensitivity in clinical trials, as a global measure, the Clinical Global Impression Scale is not specific to the signs and symptoms of the disorder under study. Development of key anchors for the scale, specific to the disorder being assessed, holds promise for enhancing the validity and reliability of the measure for disorders such as Rett syndrome.
Rett syndrome is a genetically based neurodevelopmental disorder usually caused by mutations in the gene Methyl-CpG-binding Protein 2 (MECP2). The disorder occurs almost exclusively in females, with current incidence rates of 1 in 10 000. 1 Young girls with Rett syndrome have apparently normal early development with an onset of regression between 6 and 18 months old including developmental arrest and loss of spoken communication, purposeful hand use, and motor skills. 2 Affected individuals also have loss or impairment of ambulation and the development of characteristic stereotyped repetitive hand movements. Additional clinical features common in Rett syndrome include a variety of autonomic and physiological abnormalities such as disordered breathing with hyperventilation and apnea, 3 abnormal heart rate variability, 4 and vasomotor disturbances. Scoliosis is common, 5 and most individuals are considered to have severe intellectual disability. 6 Individuals with Rett syndrome also have high rates (60%-79%) of seizures 7, 8 and abnormal EEGs with epileptiform abnormalities. 9 Although sudden unexpected death occurs more frequently than in the general population, 10 survival into adulthood is expected with a significant number of individuals with Rett syndrome reaching ages of 30 to 60 years. 11 Currently no pharmacologic treatments are approved specifically for the signs and symptoms of Rett syndrome. A treatment that could limit the symptom burden of Rett syndrome would be an important therapeutic advance. High-quality outcome measures are a requisite component of well-designed clinical trials in subjects with Rett syndrome. We describe the development of novel anchors specific to Rett signs and symptoms for the Clinical Global Impression Scales (Severity and Improvement). This effort was part of a clinical trial involving adolescent and adult females with Rett syndrome, which is the first industry-sponsored, multisite clinical trial in this clinical population.
The Clinical Global Impression Scale 12 is a measure of global clinical change with strong face validity. It has been widely used as an outcome measure in central nervous system clinical trials, including trials in neurodevelopmental disorders such as autism and Fragile X syndrome. 13, 14 The Clinical Global Impression Scale is a 7-point Likert-type rating scale that reflects expert clinical judgment. It includes independent severity of illness (CGI-S) and improvement (CGI-I) scales.
Despite its favorable assay sensitivity in clinical trial settings involving a number of different neuropsychiatric disorders, a disadvantage of the Clinical Global Impression Scale has been its lack of focus on the specific signs and symptoms of the disorder under study (or consideration). 15 This has diminished its utility as a primary outcome measure in clinical trials. In other developmental disorders such as fragile X syndrome and autism spectrum disorders, the scoring rubric used to ensure consistency across clinical experts in a given study has been tied to relevant ''anchors'' specific to the signs and symptoms of the disorder. The complete set of anchors can be found in the supplementary material in Tables S1 and S2. Scores of 1 and 2 for improvement are often used in clinical trials to define treatment ''responders,'' especially in trials involving episodic disorders (eg, major depressive disorder). In the current study, the full range of improvement scores (1, 2, or 3) were used to determine improvement. Our aim was to develop clinical anchors for the Clinical Global Impression Scales that would be specific to the signs and symptoms of Rett syndrome.
Methods and Results
The Clinical Global Impression Scale was administered as part of a double-blind, placebo controlled Phase 2 study of NNZ-2566 in adolescent and adult females between the ages of 16 to 45 years with Rett syndrome. NNZ-2566 is an analog of the terminal tripeptide of insulin-like growth factor 1 (IGF-1). In the brain, IGF-1 contributes to the growth of brain cells and synapses and plays an important role in repairing damaged cells. 16 The terminal tripeptide, glypromate or GPE, is cleaved from the main molecule and acts on brain cells by itself in a different manner than the full IGF-1 molecule. [16] [17] [18] NNZ-2566 is a modified synthetic version of GPE that is orally available and crosses the blood-brain barrier. 19, 20 Baseline characteristics of the participating subjects are outlined in Table 1 . Participants all had a clinical diagnosis of typical Rett syndrome and a confirmed, pathogenic MECP2 mutation. Participants were required to have a Clinical Global Impression severity score of 4 or higher at screening, and a score between 10 and 36 on the Rett Clinical Severity Scale, 21 a 13-item clinician measure of severity. See the Clinicaltrials.gov listing (NCT01703533) for the complete inclusion/exclusion criteria and full list of outcome measures.
For the Clinical Global Impression-Severity scale, a classification grid of symptom severity was created using scores from the Rett Clinical Severity Scale as a guide. The Clinical Severity Scale has been used to evaluate more than 1000 Rett syndrome children and adults enrolled in the NIH-sponsored Natural History of Rare Diseases Project for Rett syndrome 11 and in studies looking at genotype/phenotype correlations 21, 22 and epilepsy in Rett syndrome. 7 This 13-item measure provides a clinician rating of core symptoms of Rett syndrome on a Likert scale of either 0 to 4 or 0 to 5 with a maximum total score of 58. This first step provided an anchoring of the Clinical Global Impression-Severity ratings against an established clinical rating scale specific to Rett syndrome with excellent face validity and extensive longitudinal use. This is shown in Table 2 .
Since the Clinical Global Impression Scale is designed to be a global clinical assessment and not simply duplicate what can be determined by ratings of specific signs and symptoms, the next step was to develop the symptoms in the grid into narrative anchors that would provide a description of progressive levels of impairment in core signs and symptoms. In addition, general instructions provide a framework for applying the anchors in consideration of both number and severity of symptoms in the global classification. In applying the anchors to real-life cases, the signs and symptoms should be considered as a whole. An individual does not necessarily need to be impaired to the same degree across all signs/symptoms. The severity score ratings are shown in Table 3 . The full set of anchors is shown in Table  S1 in the Supplementary Materials.
Separate anchors were developed for Clinical Global Impressions Scale-Improvement. The severity scale anchors provide a detailed description of the specific signs and symptoms that may be encountered at each level of severity. Because the Improvement Scale is focused on determining change in symptoms from baseline, these anchors were developed to provide a framework for considering the following factors related to symptom severity in order to determine the global change score: duration, onset, durability of change, and the context of sign/ symptom change across the symptom domains. The Clinical Global Impression-Improvement anchors provide examples of sign/symptoms, and for scores representing important thresholds for treatment response, information on factors to differentiate between the scores is provided. The improvement scale scoring is shown in Table 3 . The full set of anchors is shown in Table S2 in the Supplementary Materials. To ensure consistency in the application of the anchors, clinician raters participated in periodic calibration sessions in which they co-rated sample Rett syndrome vignettes. Following best practice for the administration of the Clinical Global Impression Scales, scores within a 1-point difference were considered reliable. Scores within a 2-point difference or at a 1-point difference at a critical threshold score (eg, 2 vs 3 or 3 vs 4) were discussed, and a consensus decision was made on the interpretation of the anchors, so rescores were normed within an acceptable difference. Scoring of a sample vignette is also shown in Table 3 .
Discussion
This rating scheme developed for the Clinical Global Impression Scales captures clinically relevant gradations in severity and improvement of Rett-related signs and symptoms, offering the prospect of more consistent and relevant administration across research sites and studies. This report describes the early development of this novel format for the Clinical Global Impression Scales in the context of a clinical trial involving adolescent and adult females with Rett syndrome. Future analyses will examine the psychometric properties of this Rett-specific version of the Clinical Global Impression Scales in the context of this clinical trial. Further formal validation analyses will be conducted to confirm its construct and content validity, and demonstrate reliability of rater calibration across studies.
The Clinical Global Impression assessment is a widely used outcome measure in clinical trials of central nervous system disorders that has been demonstrated to be sensitive to treatment change. Having Rett-specific anchors for this measure would provide not only a valid measure of global treatment change, but co-validation of this popular change measure with other Rett measures can accelerate the development of a battery of outcome measures valid for use in clinical trials of Rett syndrome.
Advances in the understanding of the underlying pathophysiology of neurodevelopmental disorders is rapidly leading to the development of new ideas for therapeutics and the implementation of clinical trials. Excitingly, there is growing evidence of a degree of molecular and pathway convergence of various neurodevelopmental disorders, such as common alterations in mammalian target of rapamycin (mTOR) signaling in tuberous sclerosis and other neurodevelopmental disorders that provides for application of common therapeutics to different disorders. 23 That said, the specific clinical features within these disorders are distinct, and it is unlikely that a generic outcome measure can be uniformly applied across multiple disorders. One solution is to utilize the methodology outlined here to develop disease-specific anchors and scoring systems for the Clinical Global Impression Scale. This will provide the ability to capitalize on disease-specific features while allowing for cross-disease comparisons. Severely ill Much worse 7
Extremely ill Very much worse Abbreviations: CGI-S, Clinical Global Impression-Improvement; CGI-S, Clinical Global Impression-Severity.
